1. 340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer. (10th December 2020) Authors: Dorff, Tanya; Rettig, Matthew; Machiels, Jean-Pascal; Lolkema, Martijn; Autio, Karen; Greil, Richard; Rottey, Sylvie; Adra, Nabil; Salvati, Mark; Poon, Shirley; Tan, Daniel; Jurida, Gabor; Kouros-Mehr, Hosein; Fizazi, Karim; Tran, Ben; Horvath, Lisa Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. (10th December 2020) Authors: Cooke, Keegan; Estrada, Juan; Zhan, Jinghui; Werner, Jonathan; Lee, Fei; Shetty, Aditya; Smit, Marie-Anne Damiette; Salvati, Mark; Bailis, Julie Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. (9th November 2020) Authors: Cooke, Keegan; Estrada, Juan; Zhan, Jinghui; Werner, Jonathan; Lee, Fei; Shetty, Aditya; Smit, Marie-Anne Damiette; Salvati, Mark; Bailis, Julie Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy. (10th December 2020) Authors: Lueckerath, Katharina; Bailis, Julie; Current, Kyle; Salvati, Mark; Radu, Caius; Czernin, Johannes Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy. (9th November 2020) Authors: Lueckerath, Katharina; Bailis, Julie; Current, Kyle; Salvati, Mark; Radu, Caius; Czernin, Johannes Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pseudosaccharin amines as potent and selective KV1.5 blockers. Issue 21 (1st November 2015) Authors: Lloyd, John; Finlay, Heather J.; Kover, Alexander; Johnson, James; Pi, Zulan; Jiang, Ji; Neels, James; Cavallaro, Cullen; Wexler, Ruth; Conder, Mary Lee; Shi, Hong; Li, Danshi; Sun, Huabin; Chimalakonda, Anjaneya; Huang, Christine; Salvati, Mark; Levesque, Paul Journal: Bioorganic & medicinal chemistry letters Issue: Volume 25:Issue 21(2015) Page Start: 4983 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pseudosaccharin amines as potent and selective KV1.5 blockers. Issue 21 (1st November 2015) Authors: Lloyd, John; Finlay, Heather J.; Kover, Alexander; Johnson, James; Pi, Zulan; Jiang, Ji; Neels, James; Cavallaro, Cullen; Wexler, Ruth; Conder, Mary Lee; Shi, Hong; Li, Danshi; Sun, Huabin; Chimalakonda, Anjaneya; Huang, Christine; Salvati, Mark; Levesque, Paul Journal: Bioorganic & medicinal chemistry letters Issue: Volume 25:Issue 21(2015) Page Start: 4983 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗